Company news

Capricor Therapeutics, Inc. news in 2020

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients

December 28, 2020

Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19

November 23, 2020

Capricor Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 11, 2020

Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19

November 8, 2020

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020

September 22, 2020

Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

August 24, 2020

Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 5, 2020

Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 13, 2020

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002

May 12, 2020

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy

April 2, 2020

Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 17, 2020

Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion

March 16, 2020

Calls in 2020

Decks in 2020